PASC Post Acute Sequelae of COVID-19Early Phase 1NCT07076862
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
A Early Phase 1 study testing A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) and B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) in people with PASC Post Acute Sequelae of COVID-19, run by University of California, Davis at 2 sites in United States.
Trial summary
This study uses total-body [¹⁸F]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- PASC Post Acute Sequelae of COVID-19
- What is being tested?
- A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) and B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 51 participants
- Where
- 2 sitesUnited States
- Study dates
- 4 Dec 2025to Dec 2029
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Ability to understand the purposes and risks of the trial and willingness to sign an IRB-approved informed consent form.
- Willingness and ability to comply with all protocol required procedures.
- For participants of reproductive potential, defined as individuals who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy, willingness to use effective double barrier contraceptive methods (excluding withdrawal or timing methods) during the study and up to 1 day after the last administration of the radiotracer.
- Previous diagnosis of SARS-CoV-2 infection as defined by a prior positive SARS-CoV-2 nucleic acid-based diagnostic test performed in a clinical laboratory on one or more nasopharyngeal or respiratory secretion samples or from an FDA-approved rapid antigen test at home. Documentation of the positive test will be requested but not required; if not available the participant will be asked to attest to the presence of a positive test.
- Onset of COVID-19 symptoms (or if no symptoms, time of initial nucleic acid or antigen-based diagnostic test) at least 3 months prior to the baseline study visit.
Show all 18Show fewer
- Ability to travel to our research sites in San Francisco and Sacramento.
- Laboratory evaluations obtained within 60 days prior to entry:
- Hemoglobin ≥ 8g/dL
- Platelet count ≥ 75,000 cells/mm3
- Absolute neutrophil count (ANC) > 1000 cells/mm3
- Aspartate aminotransferase (AST) < 3 × ULN units/L
- Alanine aminotransferase (ALT) < 3 × ULN units/L
- Calculated creatinine clearance (CrCl) ≥ 60mL/min as estimated by the Cockcroft-Gault equation:
- For men, (140 - age in years) × (body weight in kg) ÷ (serum creatinine in mg/dL × 72) = CrCl (mL/min)
- For women, multiply the result by 0.85 = CrCl (mL/min)
- For PASC participants only: Reporting at least 2 unexplained symptoms, with at least 1 symptom in the fatigue domain and at least 1 symptom in either cardiopulmonary or neurocognitive domains, that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms may be new onset after initial COVID-19 recovery or persist from the initial acute phase and may fluctuate or relapse over time. (According to World Health Organization definition of PASC http://www.WHO.int )
- For control participants only: Individuals who have made full clinical recovery within 4-12 weeks of acute COVID-19 infection with no newly developed symptoms or changes in health after recovery.
Who cannot join
- Serious comorbidities (nonmalignant disease or other conditions) that in the opinion of the investigator could compromise protocol objectives.
- Any condition that alters the function of their immune system or any conditions caused by malfunction of their immune system and would interfere with imaging, including known underlying inflammatory or immune disorders, systemic malignancy, or other chronic viral infections (such as HIV, hepatitis B and hepatitis C).
- Received vaccination of any type, including a SARS-CoV-2 vaccine, within 30 days of imaging
- Pregnant or nursing individuals. A urine or HCG serum pregnancy test with a sensitivity of at least 25 mIU/mL will be performed at screening and on the day of PET/CT imaging at no charge to all participants of reproductive potential (see definition above).
- Participants who have had prior allogeneic stem cell or solid organ transplant.
- Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry.
Show all 14Show fewer
- Active systemic autoimmune diseases not related to COVID-19.
- Self-reported history of dysphoria or anxiety in closed spaces (i.e., uncontrolled claustrophobia).
- Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.
- Body weight is more than 240 kg (529 pounds)
- Prisoners
- Life expectancy < 24 months
- Recent use of medication including guanosine or cysteine analogs.
- Any other criteria which would make the participant unsuitable for enrollment to this study, as determined by the Principal Investigator.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Lynn Ngo contact
United States2 sites, 2 recruiting
- Recruiting
UC Davis EXPLORER Molecular Imaging Center
Sacramento, California, 95816
Clinical Research Team, 415-502-2449, LIINC@ucsf.edu
Negar Omidvari, PhD
- Recruiting
University of California San Francisco
San Francisco, California, 94110
LIINC Study Team, 415-502-2449, LIINC@ucsf.edu
Timothy Henrich, MD
About this study
Official title: Multiparametric Total-Body [18F]F-AraG PET/CT Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
This study uses total-body [¹⁸F]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.
Read the detailed description
Post-acute sequelae of SARS-CoV-2 infection (PASC) is associated with persistent immune dysregulation affecting multiple organ systems. This prospective, non-randomized, open-label research study will apply high-sensitivity total-body PET/CT imaging using the investigational radiotracer [¹⁸F]F-AraG to map immune activation across diverse tissues in PASC and COVID-19-recovered control participants. The tracer, [¹⁸F]F-AraG, selectively accumulates in activated T cells and allows kinetic modeling of immune cell activity in vivo.
A total of 51 participants will be enrolled, including 34 PASC participants and 17 controls. All participants will undergo baseline imaging, and a subset of 17 PASC participants will complete two additional follow-up scans at 4 and 8 months. Each imaging visit includes a dynamic PET/CT scan, peripheral blood draws for plasma proteomics and immunophenotyping, and symptom questionnaires collected through the UCSF LIINC cohort.
Findings will be used to identify tissue-specific immune signatures associated with symptom phenotypes and assess how these evolve over time. The results will help clarify the biological basis of PASC and support the development of future diagnostic or monitoring strategies. No direct health benefit is anticipated for participants.
- Conditions
- PASC Post Acute Sequelae of COVID-19
- Being tested
- A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)Drug
Participants receive an intravenous injection of 5 mCi (±20%) of [¹⁸F]F-AraG followed by a 90-minute total-body PET/CT scan and an additional 30-minute static scan at 4 hours post-injection. Blood samples (up to 42 mL total) are collected during dynamic imaging.
A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)Drug
Participants receive an intravenous injection of 5 mCi (±20%) of [¹⁸F]F-AraG followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)Drug
Participants receive an intravenous injection of 5 mCi (±20%) of [¹⁸F]F-AraG followed by a 90-minute total-body PET/CT scan and a second 30-minute scan at 4 hours. Blood samples (up to 42 mL total) are collected during dynamic imaging.
B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)Drug
Participants receive 5 mCi (±20%) of [¹⁸F]F-AraG intravenously followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
| Study group | Role | What they receive |
|---|---|---|
| A.1 - Control Group (90-min dynamic + 4-h static PET/CT) | Experimental | Control participants in this arm will undergo a 90-minute dynamic [¹⁸F]F-AraG total-body PET/CT scan, followed by a second 30-minute static PET/CT scan approximately 4 hours after tracer injection. Blood samples will be collected during the dynamic scan to support kinetic modeling. Receives: Drug: A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) |
| A.2 - Control Group (60-min dynamic PET/CT only) | Experimental | Control participants in this arm will undergo a 60-minute dynamic [¹⁸F]F-AraG total-body PET/CT scan. No delayed imaging will be performed. Blood samples will be collected during the dynamic scan. Receives: Drug: A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) |
| B.1 - PASC Group (90-min dynamic + 4-h static PET/CT) | Experimental | PASC participants in this arm will undergo a 90-minute dynamic [¹⁸F]F-AraG total-body PET/CT scan, followed by a second 30-minute static scan approximately 4 hours post-injection. Blood samples are collected during the scan. Receives: Drug: B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) |
| B.2 - PASC Group (60-min dynamic PET/CT only) | Experimental | PASC participants in this arm will undergo a 60-minute dynamic [¹⁸F]F-AraG PET/CT scan. No delayed imaging is performed. Blood samples are collected during imaging. Receives: Drug: B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantification of [¹⁸F]F-AraG uptake kinetics in PASC and control participants
To assess immune activation in convalescent COVID-19, dynamic PET/CT scans will be analyzed to generate time-activity curves (TACs) in multiple tissues. Kinetic modeling will be applied to extract uptake parameters including SUV, SUVR, Vt, Ki, and k3. These values will be reported and statistically compared between PASC and control participants.
Measured: Baseline Imaging Visit
Correlation between [¹⁸F]F-AraG uptake parameters and blood-based markers of immune dysregulation
Spearman correlation tests and heat map clustering will be used to assess the association between PET-derived uptake measures and plasma biomarkers of inflammation and immune activation. Correlations will be examined in tissues showing significant uptake differences between study groups.
Measured: Baseline imaging visit and baseline blood draw
Longitudinal change in [¹⁸F]F-AraG uptake and correlation with PASC symptom scores
In a subset of participants, follow-up PET/CT imaging at 4 and 8 months will be used to assess within-subject change in kinetic uptake parameters. These changes will be compared to changes in symptom burden as measured by PHQ-15 symptom domain scores.
Measured: Baseline, 4-month, and 8-month follow-up visits (subset of PASC participants only)
Secondary outcomes (2)
Feasibility of blood flow kinetic modeling using early [¹⁸F]F-AraG dynamic PET data
Early-phase TACs (< 5 min post-injection) will be fitted using the AATH model to estimate blood flow from the vascular phase of radiotracer distribution. Identifiability of kinetic parameters associated with vascular function will be evaluated. Mean values will be compared between study groups.
Measured: Baseline imaging visit
Correlation between vascular imaging parameters and blood biomarkers of vascular dysfunction
Spearman correlations and heatmap analyses will be used to examine associations between PET-derived vascular parameters and plasma markers of vascular dysfunction.
Measured: Baseline imaging visit and baseline blood draw
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2025
- Study start4 Dec 2025
- Primary completionDec 2028 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PASC Post Acute Sequelae of COVID-19Studies of the same condition, open and under way.
- More trials run by University of California, DavisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be enrolled into one of four parallel imaging subgroups based on disease status and study group assignment. No crossover will occur.
- Masking
- None (open label)
- Enrolment
- 51 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Davis
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
- Responsible party
- Sponsor
- Investigators
- Negar Omidvari, PhD, Principal investigator, University of California, Davis
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07076862
- Sponsor's protocol ID
- 2339805
- Other IDs
- 1R01AI185685-01A1
- Status last verified
- May 2026
- First submitted
- 10 Jul 2025
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multiparametric Total-Body [18F]F-AraG PET/CT Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
- ClinicalTrials.gov ID
- NCT07076862
- Acronym / sponsor ID
- 2339805
- Conditions
- PASC Post Acute Sequelae of COVID-19
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 51 participants (estimated)
- Lead sponsor
- University of California, DavisUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
- Study start
- 4 Dec 2025 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 22 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study uses total-body [¹⁸F]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.
Detailed description
Post-acute sequelae of SARS-CoV-2 infection (PASC) is associated with persistent immune dysregulation affecting multiple organ systems. This prospective, non-randomized, open-label research study will apply high-sensitivity total-body PET/CT imaging using the investigational radiotracer [¹⁸F]F-AraG to map immune activation across diverse tissues in PASC and COVID-19-recovered control participants. The tracer, [¹⁸F]F-AraG, selectively accumulates in activated T cells and allows kinetic modeling of immune cell activity in vivo.
A total of 51 participants will be enrolled, including 34 PASC participants and 17 controls. All participants will undergo baseline imaging, and a subset of 17 PASC participants will complete two additional follow-up scans at 4 and 8 months. Each imaging visit includes a dynamic PET/CT scan, peripheral blood draws for plasma proteomics and immunophenotyping, and symptom questionnaires collected through the UCSF LIINC cohort.
Findings will be used to identify tissue-specific immune signatures associated with symptom phenotypes and assess how these evolve over time. The results will help clarify the biological basis of PASC and support the development of future diagnostic or monitoring strategies. No direct health benefit is anticipated for participants.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Participants will be enrolled into one of four parallel imaging subgroups based on disease status and study group assignment. No crossover will occur.
| Arm | Type | Receives |
|---|---|---|
| A.1 - Control Group (90-min dynamic + 4-h static PET/CT) | Experimental | Drug: A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)Control participants in this arm will undergo a 90-minute dynamic [¹⁸F]F-AraG total-body PET/CT scan, followed by a second 30-minute static PET/CT scan approximately 4 hours after tracer injection. Blood samples will be collected during the dynamic scan to support kinetic modeling. |
| A.2 - Control Group (60-min dynamic PET/CT only) | Experimental | Drug: A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)Control participants in this arm will undergo a 60-minute dynamic [¹⁸F]F-AraG total-body PET/CT scan. No delayed imaging will be performed. Blood samples will be collected during the dynamic scan. |
| B.1 - PASC Group (90-min dynamic + 4-h static PET/CT) | Experimental | Drug: B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)PASC participants in this arm will undergo a 90-minute dynamic [¹⁸F]F-AraG total-body PET/CT scan, followed by a second 30-minute static scan approximately 4 hours post-injection. Blood samples are collected during the scan. |
| B.2 - PASC Group (60-min dynamic PET/CT only) | Experimental | Drug: B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)PASC participants in this arm will undergo a 60-minute dynamic [¹⁸F]F-AraG PET/CT scan. No delayed imaging is performed. Blood samples are collected during imaging. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Age ≥ 18 years
- Ability to understand the purposes and risks of the trial and willingness to sign an IRB-approved informed consent form.
- Willingness and ability to comply with all protocol required procedures.
- For participants of reproductive potential, defined as individuals who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy, willingness to use effective double barrier contraceptive methods (excluding withdrawal or timing methods) during the study and up to 1 day after the last administration of the radiotracer.
- Previous diagnosis of SARS-CoV-2 infection as defined by a prior positive SARS-CoV-2 nucleic acid-based diagnostic test performed in a clinical laboratory on one or more nasopharyngeal or respiratory secretion samples or from an FDA-approved rapid antigen test at home. Documentation of the positive test will be requested but not required; if not available the participant will be asked to attest to the presence of a positive test.
Key exclusion criteria (14 listed)
- Serious comorbidities (nonmalignant disease or other conditions) that in the opinion of the investigator could compromise protocol objectives.
- Any condition that alters the function of their immune system or any conditions caused by malfunction of their immune system and would interfere with imaging, including known underlying inflammatory or immune disorders, systemic malignancy, or other chronic viral infections (such as HIV, hepatitis B and hepatitis C).
- Received vaccination of any type, including a SARS-CoV-2 vaccine, within 30 days of imaging
- Pregnant or nursing individuals. A urine or HCG serum pregnancy test with a sensitivity of at least 25 mIU/mL will be performed at screening and on the day of PET/CT imaging at no charge to all participants of reproductive potential (see definition above).
- Participants who have had prior allogeneic stem cell or solid organ transplant.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)Participants receive an intravenous injection of 5 mCi (±20%) of [¹⁸F]F-AraG followed by a 90-minute total-body PET/CT scan and an additional 30-minute static scan at 4 hours post-injection. Blood samples (up to 42 mL total) are collected during dynamic imaging. | Drug | A.1 - Control Group (90-min dynamic + 4-h static PET/CT) |
| A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)Participants receive an intravenous injection of 5 mCi (±20%) of [¹⁸F]F-AraG followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging. | Drug | A.2 - Control Group (60-min dynamic PET/CT only) |
| B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)Participants receive an intravenous injection of 5 mCi (±20%) of [¹⁸F]F-AraG followed by a 90-minute total-body PET/CT scan and a second 30-minute scan at 4 hours. Blood samples (up to 42 mL total) are collected during dynamic imaging. | Drug | B.1 - PASC Group (90-min dynamic + 4-h static PET/CT) |
| B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)Participants receive 5 mCi (±20%) of [¹⁸F]F-AraG intravenously followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging. | Drug | B.2 - PASC Group (60-min dynamic PET/CT only) |
Primary outcome
Quantification of [¹⁸F]F-AraG uptake kinetics in PASC and control participants
Time frame: Baseline Imaging Visit
To assess immune activation in convalescent COVID-19, dynamic PET/CT scans will be analyzed to generate time-activity curves (TACs) in multiple tissues. Kinetic modeling will be applied to extract uptake parameters including SUV, SUVR, Vt, Ki, and k3. These values will be reported and statistically compared between PASC and control participants.
Correlation between [¹⁸F]F-AraG uptake parameters and blood-based markers of immune dysregulation
Time frame: Baseline imaging visit and baseline blood draw
Spearman correlation tests and heat map clustering will be used to assess the association between PET-derived uptake measures and plasma biomarkers of inflammation and immune activation. Correlations will be examined in tissues showing significant uptake differences between study groups.
Longitudinal change in [¹⁸F]F-AraG uptake and correlation with PASC symptom scores
Time frame: Baseline, 4-month, and 8-month follow-up visits (subset of PASC participants only)
In a subset of participants, follow-up PET/CT imaging at 4 and 8 months will be used to assess within-subject change in kinetic uptake parameters. These changes will be compared to changes in symptom burden as measured by PHQ-15 symptom domain scores.
2 secondary outcomes
Feasibility of blood flow kinetic modeling using early [¹⁸F]F-AraG dynamic PET data
Time frame: Baseline imaging visit
Correlation between vascular imaging parameters and blood biomarkers of vascular dysfunction
Time frame: Baseline imaging visit and baseline blood draw
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No
Related trials for PASC Post Acute Sequelae of COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
Active, not recruitingObservational study
Pain in Long COVID-19: The Role of Sleep
Long COVID
Active, not recruiting
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lynn Ngo contact
Negar Omidvari, PhD principal investigator
University of California, Davis
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) and B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) in people with PASC Post Acute Sequelae of COVID-19, run by University of California, Davis at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Research Team (415-502-2449, LIINC@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantification of [¹⁸F]F-AraG uptake kinetics in PASC and control participants (time frame: Baseline Imaging Visit). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.